



"I got AstraZeneca for my first dose. Which vaccine should I get for my second?"

1	Getting AstraZeneca for your first dose was the right decision. It's protecting you and others from severe Covid-19.			
2	Now, it's most important to get a sec helps you be fully immunized and pro		I dose of any vaccine. Any second dose ts you better against the variants.	
3	Deciding on either AstraZeneca or Moderna or Pfizer* for your second dose: *Moderna and Pfizer have similar benefits and side effects. It doesn't matter which one you get.			
	AstraZeneca		Moderna or Pfizer	
	A second dose of AstraZeneca may offer less protection against the variants than Moderna or Pfizer.		A second dose of Moderna or Pfizer may offer more protection against the variants than AstraZeneca.	
	It might be best to get AstraZeneca now if you have to wait several weeks for Moderna or Pfizer.		Canada has a large supply of Moderna and Pfizer. They may be easier to find than AstraZeneca.	
	The risk of a severe blood clotting disorder from the second dose of AstraZeneca is estimated to be 1 in 600,000. [†] [†] This number may change as we learn more.		There is no known risk of blood clots with Moderna or Pfizer.	
	With any vaccine you get for your second dose (AstraZeneca, Moderna, or Pfizer), you may feel more, the same, or fewer side effects than your first dose. Side effects can include a sore arm, fatigue, headache, body aches, and chills for 1-3 days.			
	Rest, fluids, and acetaminophen can h vaccines. Some people may need to t			
	This can be a tough choice. getting your second dose, as	lf y sk y	ou have questions about	

→ Want more detail? Check out our <u>6-page summary</u>.

https://uwaterloo.ca/pharmacy/sites/ca.pharmacy/files/uploads/files/i_got_astrazeneca_for_my_first_dose_what_should_i_do_for_my_second_-_long_version.pdf

https://www.canada.ca/content/dam/phac-aspc/documents/services/immunization/national-advisory-committee-on-immunization-naci/summary-interchangeability-authorized-covid-19-vaccines-en.pdf https://www.medrxiv.org/content/medrxiv/early/2021/06/02/2021.05.19.21257334.full.pdf Planas et al. bioRxiv https://doi.org/10.1101/2021.05.26.445838 **19TOZER@**

https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/991135/3_June_2021_Risk_assessment_for_SARS-CoV-2_variant_DELTA.pdf

Content by Kelly Grindrod, PharmD; Noah Ivers, MD; Samira Jeimy, MD; Rosemary Killeen, BScPhm; Tara Kiran, MD; Kate Miller, MD; Menaka Pai, MD; Vivan Smith, PhD; Sabina Vohra-Miller, MSc; Kristen Watt, BScPhm; Holly Witteman, PhD; Samantha Yammine, PhD. Design by Adrian Poon, BA.

